


PHARMACEUTICAL 2023

Rezolute Inc. Rank 22 of 446







PHARMACEUTICAL 2023



Rezolute Inc. Rank 22 of 446

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Rezolute Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 235% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	152,104
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,462
Liabilities, Non-Current	80
Other Assets	300
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	407
Other Net Income	783
Other Revenues	0
Property and Equipment	16
Research and Development	32,486
Selling, General and Administrative Expense	9,357

Output Variable	Value in 1000 USD
Assets	152,420
Liabilities	2,949
Expenses	41,843
Revenues	0
Stockholders Equity	149,471
Net Income	-41,060
Comprehensive Net Income	-41,060
Economic Capital Ratio	278%

